Matthew McCoy

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (24)

• Impact of Trastuzumab and Pertuzumab on HER2 Localization and the Estrogen Receptor Cistrome in ER+/HER2+ Breast Cancer
  2026 DOI: 10.64898/2026.09.07.749891
  +Save
• Hidden State Genomics: Graph-Based Analysis of Sparse Auto-Encoder Feature Activity in Genomic Language Models
  2026 DOI: 10.64898/2026.05.13.725007
  +Save
• PEGASUS: Unlocking Polarity in Cell-Permeable Cyclic Peptides Using AI Models Built on Massively Parallel Biological Assays
  Journal of Medicinal Chemistry 2026 DOI: 10.1021/acs.jmedchem.5c01836
  +Save
• Digital twins in oncology: where we are and where we hope to go
  BMJ Oncology 2025 DOI: 10.1136/bmjonc-2025-000893
  +Save
• Probability Distribution for Rare Neutral Mutations in Cancers and Application to Dynamic Precision Medicine of Cancer
  2025 DOI: 10.1101/2025.10.10.681641
  +Save
• Generalized Evolutionary Classifier for Evolutionary Guided Precision Medicine
  JCO Precision Oncology 2025 DOI: 10.1200/PO.23.00714
  +Save
• Personalized cancer treatment strategies incorporating irreversible and reversible drug resistance mechanisms
  2024 DOI: 10.1101/2024.11.03.621749
  +Save
• PD-L1 Expression Varies in Thyroid Cancer Types and Is Associated with Decreased Progression Free Survival (PFS) in Patients with Anaplastic Thyroid Cancer
  Leila A. Shobab, Deema Al-Souri, Liza Mathews +12 more
  Cancers 2024 DOI: 10.3390/cancers16213632
  +Save
• Sex-Specific Expression of Histone Lysine Demethylases (KDMs) in Thyroid Cancer
  Cancers 2024 DOI: 10.3390/cancers16071260
  +Save
• Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
  2023 DOI: 10.1101/2023.08.21.554116
  +Save
• All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
  2023 DOI: 10.1158/1535-7163.22521855.v1
  +Save
• All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
  2023 DOI: 10.1158/1535-7163.22521855
  +Save
• Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
  2023 DOI: 10.1158/1535-7163.c.6543201.v1
  +Save
• Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
  2023 DOI: 10.1158/1535-7163.c.6543201
  +Save
• Understanding Calmodulin Variants Affecting Calcium-Dependent Inactivation of L-Type Calcium Channels through Whole-Cell Simulation of the Cardiac Ventricular Myocyte
  Biomolecules 2022 DOI: 10.3390/biom13010072
  +Save
• HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms
  Aditi Jain, Matthew McCoy, Carolyn Coats +6 more
  Cancers 2022 DOI: 10.3390/cancers14071848
  +Save
• The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
  Molecular Cancer Therapeutics 2021 DOI: 10.1158/1535-7163.MCT-20-0652
  +Save
• Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice
  Gastroenterology 2021 DOI: 10.1053/j.gastro.2020.11.044
  +Save
• Simulating Protein Structure to Support Clinical Decisions: Predicting the Ligand Specific Impact of Genomic Variation on Opioid Binding
  2020 DOI: 10.21203/rs.3.rs-87124/v1
  +Save
• A Generalized Evolutionary Classifier for Evolutionary Guided Precision Medicine
  2020 DOI: 10.1101/2020.09.24.20201111
  +Save